1 Executive Summary
2 Ophthalmic Disorders and Treatments
2.1 The Ophthalmology Market
2.2 Ophthalmic Disorders
2.3 The Human Eye and the Vision Process
2.4 Glaucoma
2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma
2.4.2 Closed Angle Glaucoma
2.4.3 Secondary Glaucoma
2.4.4 Congenital Glaucoma
2.4.5 Normal Tension Glaucoma
2.4.6 Ocular Hypertension
2.4.7 Glaucoma Risk Factors
2.4.8 Diagnosis of Glaucoma
2.4.9 Prevalence of Glaucoma
2.4.10 Treatment of Glaucoma
2.4.11 Prostaglandins are the First-Line Treatment of Choice
2.4.12 Second-Line Glaucoma Treatments
2.4.13 Combination Treatments
2.4.14 Laser Treatment
2.4.15 Surgery (Trabeculectomy)
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry AMD
2.5.2 Wet AMD
2.5.3 AMD Risk Factors
2.5.4 Diagnosis of AMD
2.5.5 Prevalence of AMD
2.5.6 Treatment of AMD
2.6 Diabetic Retinopathy
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Prevalence of Diabetic Retinopathy
2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
2.6.4 Pharmaceutical Treatments
2.7 Ophthalmic Allergies
2.7.1 Allergic Conjunctivitis is the Most Common Eye Allergy
2.7.2 Ophthalmic Allergy Treatments
2.8 Ophthalmic Inflammatory Disorders
2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease
2.8.2 Ophthalmic Inflammatory Drugs
2.9 Ophthalmic Infections
2.9.1 Types of Eye Infection
2.9.2 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Causes and Prevalence of Dry Eye Syndrome
2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears
2.10.3 Prescription-Only Drugs for Dry Eye are Limited
2.10.4 Tear Augmenters (Punctal Plugs)
3 The Global Ophthalmic Pharmaceutical Market, 2008-2023
3.1 The Ophthalmic Pharmaceutical Market in 2007
3.1.1 Anti-Glaucoma had Largest Market Share in 2007
3.1.2 Top Twelve Ophthalmic Pharmaceutical Brands, 2007
3.1.3 Three Manufacturers Account for Almost Half the Market
3.2 Global Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market during 2008-2013
3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market during 2013-2023?
3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2008-2023
3.3.1 Two Therapeutic Categories Will Power Growth during 2008-2013
3.3.2 Retinal Disorder Drug Growth Will Continue Through 2013-2018
3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma during 2018-2023
4 The Anti-Glaucoma Market, 2008-2023
4.1 The Anti-Glaucoma Market in 2007
4.1.1 Prostaglandin Analogues Lead the Anti-Glaucoma Market in 2007
4.1.2 Xalatan/Xalacom
4.1.3 Cosopt/Trusopt
4.1.4 Travatan/Travatan Z/DuoTrav
4.1.5 Lumigan/Ganfort
4.1.6 Alphagan/Combigan
4.1.7 Azopt
4.2 Anti-Glaucoma Market Forecasts, 2008-2023
4.2.1 Generic Competition Will Impact Anti-Glaucoma Market During 2008-2013
4.2.2 Novel Glaucoma Drugs Will Drive Growth during 2013-2023
4.2.3 Xalatan/Xalacom Sales Forecast, 2008-2023
4.2.4 Cosopt/Trusopt Sales Forecast, 2008-2023
4.2.5 Travatan/Travatan Z/DuoTrav Sales Forecast, 2008-2023
4.2.6 Lumigan/Ganfort Sales Forecast, 2008-2023
4.2.7 Alphagan/Combigan Sales Forecast, 2008-2023
4.2.8 Azopt/Azarga Sales Forecast, 2008-2023
5 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2008-2023
5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market in 2007
5.1.1 Patanol/Opatanol/Pataday
5.1.2 TobraDex
5.1.3 Vigamox/Vegamox
5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2008-2023
5.2.1 Lack of Novel Pipeline Products in Anti-Allergy/Inflammatory/Infective Sector
5.2.2 Patanol/Opatanol/Pataday Sales Forecast, 2008-2023
5.2.3 TobraDex Sales Forecast, 2008-2023
5.2.4 Vigamox/Vegamox Sales Forecast, 2008-2023
6 The Retinal Disorder Market, 2008-2023
6.1 The Retinal Disorder Market in 2007
6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorder Market
6.1.2 Lucentis Took Control of the Retinal Disorder Market in 2007
6.1.3 Visudyne was the Second Highest-Selling Retinal Disorder Drug in 2007
6.1.4 Lucentis has Side-Lined Macugen but Faces Potent Threat from Avastin
6.1.5 The Diabetic Retinopathy Market
6.2 Retinal Disorder Market Forecasts, 2008-2023
6.2.1 Lucentis Will Drive the Retinal Disorder Market during 2008-2013
6.2.2 Novel Drugs and New Disease Treatments will Drive Growth during 2013-2023
6.2.3 Lucentis Sales Forecast, 2008-2023
6.2.4 Visudyne Sales Forecast, 2008-2023
7 The Dry Eye Market, 2008-2023
7.1 The Dry Eye Market in 2007
7.1.1 Restasis is the Only Prescription-Only Drug for Dry Eye in the US
7.1.2 Hyalein: Marketed in Japan and China
7.1.3 The OTC Market for Artificial Tears is Fragmented and Competitive
7.2 Dry Eye Market Forecasts, 2008-2023
7.2.1 Increased Sales of Dry Eye Prescription Drugs Forecasted During 2008-2013
7.2.2 Growth in the Dry Eye Market Will Moderate After 2013
7.2.3 Restasis Sales Forecast, 2008-2023
8 Issues Affecting the Market for Ophthalmic Pharmaceuticals
8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market
8.2 Strengths in the Ophthalmic Pharmaceutical Market
8.2.1 Development of New Drug Delivery Methods and Formulations
8.2.2 Intraocular Injections
8.2.3 Sustained-Release Ocular Implants
8.2.4 Gene Therapy and RNA Interference Technology
8.2.5 New Ophthalmic Therapeutic Applications for Drugs
8.2.6 Development of Neuroprotective Anti-Glaucoma Medications
8.3 Weaknesses in the Ophthalmic Pharmaceutical Market
8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition
8.3.2 Avastin is Cannibalising Lucentis’ Revenues
8.4 Opportunities for the Ophthalmic Pharmaceutical Market
8.4.1 The Greying of the World Population
8.4.2 Increasing Prevalence of Diabetes and Unhealthy Lifestyles
8.4.3 Increasing Prevalence of Eye Disorders
8.4.4 Retinal Disorders Will Have the Most Marked Increases in Prevalence
8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders
8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals
8.5 Threats Facing the Ophthalmic Pharmaceutical Market
8.5.1 Poor Patient Compliance
8.5.2 The Rate of Diagnosis for Eye Disorders is Low
9 Ophthalmic Pharmaceutical Country Markets
9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007
9.2 Leading Developed Country Ophthalmic Pharmaceutical Markets, 2008-2023
9.2.1 The US Ophthalmic Pharmaceutical Market
9.2.2 The Japanese Ophthalmic Pharmaceutical Market
9.2.3 European Ophthalmic Pharmaceutical Markets
9.3 Emerging Economy Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
9.3.1 Ophthalmic Pharmaceuticals are Making the Leap to Developing Countries
9.3.2 The Indian Ophthalmic Pharmaceutical Market
9.3.3 The Chinese Ophthalmic Pharmaceutical Market
10 The Ophthalmic Pharmaceutical Pipeline
10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Drugs
10.2 The Anti-Glaucoma Pipeline
10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development
10.2.2 Taflotan/DE-085 (Santen/Asahi)
10.2.3 Azarga (Alcon)
10.2.4 Anecortave (Alcon)
10.2.5 DNB-001 (Danube)
10.2.6 BVT.28949 (Biovitrum)
10.2.7 DE-092/Olmesarten (Santen)
10.2.8 OT-730 (Othera)
10.2.9 AL-37807 (Alcon)
10.2.10 PF-4217329 (Pfizer)
10.2.11 QLT’s Punctal Plug Delivery Technology
10.2.12 PF-03187207 (NicOx/Pfizer)
10.3 The Ophthalmic Anti-Allergy Pipeline
10.3.1 Bepreve (ISTA/Senju)
10.3.2 FOV1101 (Fovea/CombinatoRx)
10.3.3 DE-103 (Santen)
10.4 The Ophthalmic Anti-Inflammatory Pipeline
10.4.1 T-Pred (ISTA)
10.4.2 AzaSite Plus/ASV-502 (InSite Vision)
10.4.3 Durezol (Senju/Sirion Therapeutics)
10.4.4 Luveniq (LuxBiosciences)
10.4.5 Simulect (Cerimon)
10.4.6 EGP-437 (EyeGatePharm)
10.5 The Ophthalmic Anti-Infective Pipeline
10.5.1 TobraDex ST (Alcon)
10.5.2 ISV-403 (Besifloxacin, Bausch & Lomb)
10.5.3 Moxifloxacin/Dexamethasone (Alcon)
10.6 The Retinal Disease Pipeline
10.6.1 Retinal Diseases Have the Richest Pipeline
10.6.2 Arxxant (Eli Lilly/Alcon/Takeda)
10.6.3 Vitrase/Vitragen (ISTA)
10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer)
10.6.5 Bevasiranib/Cand5 (Opko)
10.6.6 Lucentis (Genentech/Roche/Novartis)
10.6.7 Atacand/TCV-116 (AstraZeneca/Takeda)
10.6.8 SNK-860 (Sanwa Kagaku Kenkyusho)
10.6.9 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
10.6.10 Medidur (pSivida/Alimera Sciences/Pfizer)
10.6.11 NT-501 (Neurotech)
10.6.12 Microplasmin (ThromboGenics)
10.6.13 Sustained-Release Brimonidine (Allergan)
10.6.14 RTP801i-14/PF-4523655 (Quark/Pfizer)
10.6.15 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
10.6.16 ATG-3 (CoMentis)
10.6.17 OT-551 (Othera)
10.6.18 Fenretinide (Sirion Therapeutics)
10.6.19 RPE65 Gene Therapy (Targeted Genetics)
10.7 The Dry Eye Pipeline
10.7.1 Prolacria (Inspire/Allergan/Santen)
10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)
10.7.3 Rebamipide (Otsuka/Acucela)
10.7.4 DE-101/Rivoglitazone (Santen)
10.7.5 Ecabet (ISTA)
10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth-Stimulators
11 Expert Views from Key-Opinion Leaders
11.1 Barrett Katz, M.D., M.B.A., Chief Executive Officer and Chief Medical Officer and Brian Levy, O.D., M.Sc., Chief Operating Officer, Danube Pharmaceuticals
11.1.1 Neuroprotection is the Key Unmet Need Amongst Glaucoma Patients
11.1.2 Danube’s Pipeline Anti-Glaucoma Medication: DNB-001
11.1.3 Key Threats Facing the Ophthalmic Pharmaceutical Industry
11.1.4 Major Growth Opportunities in the Ophthalmic Pharmaceutical Industry
11.1.5 The Future of the Anti-Glaucoma Market
11.2 Dr Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
11.2.1 Which Areas of the Ophthalmic Pharmaceutical Industry will have Greatest Growth?
11.2.2 Othera’s Geographic Atrophy Drug: OT-551
11.2.3 How Will Glaucoma be Treated in 2023?
11.2.4 Othera’s Neuroprotective Anti-Glaucoma Drug: OT-440
11.2.5 Othera’s New Generation Beta Blocker: OT-730
11.2.6 New Drugs for Ophthalmic Conditions Currently with No Treatments
12 Conclusions
12.1 The Ophthalmic Pharmaceutical Market in 2007
12.2 Visiongain’s Ophthalmic Pharmaceutical Market Forecast, 2008-2023
12.3 Who Will Succeed in the Ophthalmic Pharmaceutical Marketplace?
12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?
List of Tables
Table 2.1 Major Glaucoma Pharmaceutical Types
Table 2.2 Major AMD Drugs
Table 2.3 Ophthalmic Allergy Drug Types
Table 2.4 Ophthalmic Inflammatory Disorder Drug Types
Table 2.5 Key Ophthalmic Anti-Infective Drug Types
Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Share, 2007
Table 3.2 Top-Twelve Ophthalmic Pharmaceutical Brands, 2007
Table 3.3 Top-Eight Ophthalmic Pharmaceutical Manufacturers, 2007
Table 3.4 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2013
Table 3.5 Global Ophthalmic Pharmaceutical Market Forecast, 2014-2023
Table 3.6 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2008-2013
Table 3.7 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2014-2023
Table 4.1 Leading Anti-Glaucoma Brands, 2007
Table 4.2 World Anti-Glaucoma Market Forecast, 2008-2013
Table 4.3 World Anti-Glaucoma Market Forecast, 2014-2023
Table 4.4 Leading Anti-Glaucoma Brands Sales Forecast, 2008-2013
Table 4.5 Leading Anti-Glaucoma Brands Sales Forecast, 2014-2023
Table 5.1 Therapeutic Category Market Share in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2007
Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands, 2007
Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2008-2013
Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2014-2023
Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecast, 2008-2013
Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecast, 2014-2023
Table 6.1 Therapeutic Category Market Share in the Retinal Disorder Market, 2007
Table 6.2 Leading Retinal Disorder Brands, 2007
Table 6.3 World Retinal Disorder Market Forecast, 2008-2013
Table 6.4 World Retinal Disorder Market Forecast, 2014-2023
Table 6.5 Leading Retinal Disorder Brands Sales Forecast, 2008-2013
Table 6.6 Leading Retinal Disorder Brands Sales Forecast, 2014-2023
Table 7.1 Leading Dry Eye Brands, 2007
Table 7.2 World Dry Eye Market Forecast, 2008-2013
Table 7.3 World Dry Eye Market Forecast, 2014-2023
Table 7.4 Restasis Sales Forecast, 2008-2013
Table 7.5 Restasis Sales Forecast, 2014-2023
Table 8.1 SWOT Chart for the Ophthalmic Pharmaceutical Market
Table 8.2 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2008-2014
Table 8.3 Global Ophthalmic Disorder Prevalence Forecast, 2007-2030
Table 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007
Table 9.2 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2008-2013
Table 9.3 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2014-2023
Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline
Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline
Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline
Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline
Table 10.5 Key Drugs in the Retinal Disease Pipeline: 1
Table 10.6 Key Drugs in the Retinal Disease Pipeline: 2
Table 10.7 Key Drugs in the Dry Eye Pipeline
Table 10.8 Key Pipeline Drugs for Other Ophthalmic Indications
List of Figures
Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Share, 2007
Figure 3.2 Top-Eight Ophthalmic Pharmaceutical Manufacturers, 2007
Figure 3.3 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2023
Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Share and Forecast, 2008-2023
Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2008-2023
Figure 4.1 Leading Anti-Glaucoma Brands, 2007
Figure 4.2 World Anti-Glaucoma Market Forecast, 2008-2023
Figure 4.3 Leading Anti-Glaucoma Brands, 2013
Figure 4.4 Xalatan/Xalacom Sales Forecast, 2008-2023
Figure 4.5 Cosopt/Trusopt Sales Forecast, 2008-2023
Figure 4.6 Travatan/Travatan Z/DuoTrav Sales Forecast, 2008-2023
Figure 4.7 Lumigan/Ganfort Sales Forecast, 2008-2023
Figure 4.8 Alphagan/Combigan Sales Forecast, 2008-2023
Figure 4.9 Azopt/Azarga Sales Forecast, 2008-2023
Figure 5.1 Therapeutic Category Market Share in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2007
Figure 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2008-2023
Figure 5.3 Patanol/Opatanol/Pataday Sales Forecast, 2008-2023
Figure 5.4 TobraDex Sales Forecast, 2008-2023
Figure 5.5 Vigamox/Vegamox Sales Forecast, 2008-2023
Figure 6.1 Therapeutic Category Market Share in the Retinal Disorder Market, 2007
Figure 6.2 Leading Retinal Disorder Brands, 2007
Figure 6.3 World Retinal Disorder Market Forecast, 2008-2023
Figure 6.4 Lucentis Sales Forecast, 2008-2023
Figure 6.5 Visudyne Sales Forecast, 2008-2023
Figure 7.1 World Dry Eye Market Forecast, 2008-2023
Figure 7.2 Restasis Sales Forecast, 2008-2023
Figure 8.1 Global Population Aged Over 65, 2007-2023
Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2007 and 2023
Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030
Figure 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007
Figure 9.2 Leading Ophthalmic Pharmaceutical Country Markets, 2013
Figure 9.3 Leading Ophthalmic Pharmaceutical Country Markets, 2018
Figure 9.4 Leading Ophthalmic Pharmaceutical Country Markets, 2023
Figure 9.5 US and Japanese Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
Figure 9.6 European, Brazilian, Indian and Chinese Ophthalmic Pharmaceutical Market Forecasts, 2008-2023
Figure 12.1 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2023